You are on page 1of 11

.

, ,
.
,
.
, , (75 mg)
, .

, , .
.
, ,
.
.
.

C .
, 50 C (5 1 ), ,
.
C 1 (87 55 %) 4 (63 45%) .
C.
500 1000 mg 3 , .

.
, .
45 .
, .
, , , ,
.
, .
400 800 ..

C
( )
.
, , C
, .
20
, , , ,
.
(400 3 ) C ( 500 mg 3 ).
.

, .
.
, ,
.
, (200 400 mg ).
, () (200- 400 mg ).
, .
.

, , , , , .
, , , , .
Indian Institute of Toxicology .

Study shows curcumin protects against mercury exposure


3000 -

D aitake

maitake (Grifola frondosa) .


1984, D
. (1)
, , ,
.
maitake ( -) .
.
maitake ,
.
, .
,
.
, .
,
.
, (Saccharomyces cerevisiae) maitake,
.

maitake .
1. .
2. .
3. ().

4. () .
D D .
, .
maitake , -1, -2,
, .
.
,
.
maitake , , ,
, , , , .
1994 63 .
95% 90%.
50% , , .
maitake
.

Q10

1998, Q0
.
, ,
, , 40 mg , 2800 mg .
20 mg , 1400 mg , 10
mg /, 700 mg .

, .
.
, , ( ),
, , (
). (2)
, , .
( )
. (3)
, - ,
. (4)
, , ,
. (5)
,
( - ) . (6)
,
. (7)
( )
, , .
, ( ) ,
, . (8)
, , , ,

. (9)
.
, . (10)

,
, , , , , , , ,
.
, ,
, -
. (11) (12)
Summary of Studies Using Melatonin
Lissonis Phase II Randomized Clinical Trial Results

100

20 mg

6%

0%

63

10 mg

6%

1%

30

10 mg

M43%

1%

14

20 mg

64%

36%

30

20 mg

38%

12%

50

IL -2

40 mg

36%

12%

60

IL-2

40 mg

24%

19%

Adapted from Life Extension (March 2002). Originally compiled by Cancer Treatment Centers of America.
http://http://www.lef.org/magazine/mag2004/jan2004_report_melatonin_05.htm

( )


Brohult , () ,
, . (13) (14)
, AK
, . (15)
1986 , .
284 , ,
.
525 .
AK 88%, 82% .
, AKG .
- , 51 %
.
,
, 60.(16)
AK ,
. (17)
AK ,
, . (18)
.
AK C,
. (19) (20)
AK
.(21) (22)

.
, AK .
AKG
. (23)
2003,
, , , .
, ,
AK ,
, .
, . . . ,
. .
,
.
.
, AK oil. (24) (25)


Dr Michael Murray
http://www.lef.org/magazine/mag2005/aug2005_report_shark_02.htm
http://www.ncbi.nlm.nih.gov/pubmed


B sc

1.http://www.ncbi.nlm.nih.gov/pubmed/12126464
2.Cancer Drug Resistance.Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy.
Semin Oncol. 2001;28:29-35.
3.Lissoni P, Bucovec R, Bonfanti A, et al. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancerrelated thrombocytopenia. J Pineal Res. 2001;30:123-126.
4.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662383/
5.Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol.
2000;17:869-879.
6.Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6:3-9.
7.Granzotto M, Rapozzi V, Decorti G, Giraldi T. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal
Res. 2001;31:206-213.
8.Antioxidative Effects of Melatonin in Protection Against Cellular Damage Caused by Ionizing Radiation
http://Magorzata Karbownik1,2, Russel J. Reiter1, Article first published online: 18 JUL 2008 DOI: 10.1111/j.1525-1373.2000.22502.x
9.Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.

http://www.ncbi.nlm.nih.gov/pubmed/8570130
10.Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their
implications for circadian-based cancer therapy. Curr Topics in Med Chem. 2002;2:113-132.
11.Jatoi A, Thomas CR, Jr. Esophageal cancer and the esophagus: Challenges and potential strategies for selective cytoprotection of the tumor-bearing organ
during cancer treatment. Semin Radiat Onc. 2002;12:62-67.
12.Deoxyribonuclease I is Essential for DNA Fragmentation Induced by Gamma Radiation in Mice
13.Regression of tumour growth after administration of alkoxyglycerols.
14.Boeryd B, Hallgren B, Stallberg G. Studies on the effect of methoxy-substituted glycerol ethers on tumour growth and metastasis formation. Br J Exp Pathol.
1971 Jun;52(3):221-30.
15.Pedrono F, Khan NA, Legrand AB. Regulation of calcium signalling by 1-O-alkylglycerols in human Jurkat T lymphocytes. Life Sci. 2004 Apr 16;74(22):2793801.
16.Brohult A, Brohult J, Brohult S, Joelsson I. Reduced mortality in cancer patients after administration of alkoxyglycerols. Acta Obstet Gynecol Scand.
1986;65(7):779-85.
17.Solomon N, Passwater R, Joelsson I, Haimes L. Shark Liver Oil: Natures Amazing Healer. Kensington Books; 1997.
18.Brohult A, Brohult J, Brohult S, Joelsson I. Reduced mortality in cancer patients after administration of alkoxyglycerols. Acta Obstet Gynecol Scand.
1986;65(7):779-85.
19.Pugliese PT, Jordan K, Cederberg H, Brohult J. Some biological actions of alkylglycerols from shark liver oil. J Altern Complement Med. 1998;4(1):87-99.
20.Aroca JD, Sanchez-Pinera P, Corbalan-Garcia S, et al. Correlation between the effect of the anti-neoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3phosphocholine on the membrane and the activity of protein kinase Calpha. Eur J Biochem. 2001 Dec;268(24):6369-78.
21.Krotkiewski M, Przybyszewska M, Janik P. Cytostatic and cytotoxic effects of alkylglycerols (Ecomer). Med Sci Monit. 2003 Nov;9(11):I131-5.
22.Yamamoto N, St CD, Jr., Homma S, Ngwenya BZ. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer
Res. 1988 Nov 1;48(21):6044-9.
23.Wang H, Rajagopal S, Reynolds S, Cederberg H, Chakrabarty S. Differentiation-promoting effect of 1-O (2 methoxy) hexadecyl glycerol in human colon
cancer cells. J Cell Physiol. 1999 Feb;178(2):173-8.
24.Pedrono F, Martin B, Leduc C, et al. Natural alkylglycerols restrain growth and metastasis of grafted tumors in mice. Nutr Cancer. 2004;48(1):64-9.
25.Skopinska-Rozewska E, Krotkiewski M, Sommer E, et al. Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic
sarcoma L-1, human urinary bladder and human kidney tumour cells. Oncol Rep. 1999 Nov;6(6):1341-4.